Radiotherapy Treatments for Neoplasms in the Abdominal-pelvic Region

NCT06335238 | Recruiting

• 1 other identifier: IEO 0729
• Study Type: observational
• Target: 7,700
• Locations: 1 country
• Sites: 1

Brief Summary

Evaluation of clinical and dosimetric aspects, tolerance, and effectiveness of abdominal-pelvic region radiotherapy treatments in patients undergoing radiotherapy for primary or secondary neoplasms localized in the abdominal-pelvic region.

Conditions

Abdominal Cancer; Pelvic Cancer

Outcome Measures

Primary Outcomes (2)

• Overall survival

  Number of patients death

  5 years

• Disease free survival

  Number of oncological event (local recurrence, distant metastasis, other primary tumor)

  5 years

Study Arms (1)

Radiotherapy to abdominal-pelvic region

Collection of data of patients receiving RadioTherapy (RT) to abdominal-pelvic region

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients treated at European Institute of Oncology with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the abdominal-pelvic region

You may qualify if:

• Patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the abdominal-pelvic region for:
• Primary tumors of the gastrointestinal tract, Primary tumors of the male and female reproductive systems, Primary tumors of the urinary system, Primary tumors of the cardio-circulatory system, Primary tumors of the lymphatic system, Primary tumors of the nervous system, Skin tumors, Secondary abdominal-pelvic localizations of various origins, Primary or secondary bone or soft tissue lesions of the lumbosacral spine and pelvis.
• Signed informed consent

You may not qualify if:

• \. Radiotherapy in districts other than the abdominal-pelvic region

Sponsors & Collaborators

• European Institute of Oncology: lead

Study Sites (1)

European Institute of Oncology

Milan, Italy

RECRUITING

MeSH Terms

Conditions

Pelvic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms

Study Officials

• Barbara Alicja Jereczek

  European Institute of Oncology

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Barbara Alicja Jereczek

CONTACT

+39 02 57489326; barbara.jereczek@ieo.it

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 22, 2024
• First Posted: March 28, 2024
• Study Start: February 22, 2018
• Primary Completion: December 31, 2024
• Study Completion: December 31, 2024
• Last Updated: August 5, 2024

Record last verified: 2024-03

Locations

IT (1)